Protalix BioTherapeutics (Israel) Profile

ILS 11.80  6.14%

Protalix BioTherapeutics Summary

Protalix BioTherapeutics Inc (PLX) is traded on Tel Aviv Stock Exchange in Israel. It is located in 2 Snunit Street and employs 232 people. The company currently falls under 'Small-Cap' category with current market capitalization of 336.8 M. Protalix BioTherapeutics Inc has 133.84 M outstanding shares. PROTALIX BIOTCS has accumulated about 33.48 M in cash with (34.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24.
Check Protalix BioTherapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Exposer

PriceHorizonTargetAbove OddsBelow Odds
 203.90 30 days 203.90  about 24.64% about 75.31%
Based on normal probability distribution, the odds of Protalix BioTherapeutics to move above current price in 30 days from now is about 24.64%.

Protalix BioTherapeutics Risk Profiles

Key Fundamentals

Protalix BioTherapeutics Against Markets

Current Ratings

Protalix BioTherapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 44% 
Equity ratings for Protalix BioTherapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Protalix BioTherapeutics is traded on Tel Aviv Stock Exchange in Israel. more
NameProtalix BioTherapeutics Inc
CEO and President and DirectorMoshe ManorView All
Macroaxis Advice
InstrumentIsrael Stock View All
Business Address2 Snunit Street
Foreign Associate  USA
ExchangeTel Aviv Stock Exchange
Contact Number972 4 988 9488
CurrencyILS - Israeli Shekel

Current Sentiment - PLX

Protalix BioTherapeutics Investor Sentiment
Most of Macroaxis users are at this time bullish on Protalix BioTherapeutics Inc. What is your perspective on investing in Protalix BioTherapeutics Inc? Are you bullish or bearish?
98% Bullish
2% Bearish
Skip  Hide

Diversify with Protalix BioTherapeutics Inc

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Protalix BioTherapeutics Inc to your portfolio


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Protalix BioTherapeutics Corporate Directors
Roger Kornberg Independent Director, Ph.D
Amos BarShalev Independent Director, MBA
Aharon Schwartz Independent Director, Ph.D